Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment

Medical Principles and Practice

Volumn 19, Issue 1, 2009, Pages 68-72

  Matsumura, Mihoko ^a   Monden, Tsuyoshi ^a   Nakatani, Yuki ^a   Shimizu, Hiroaki ^a   Domeki, Nozomi ^a   Yanagi, Kazunori ^a   Ikeda, Shiori ^a   Kawagoe, Yoshiaki ^a   Kasai, Kikuo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Lipid; Low density lipoprotein cholesterol; Raloxifene; Type 2 diabetes

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ATORVASTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RALOXIFENE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; JAPANESE; LIPID BLOOD LEVEL; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE OSTEOPOROSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BONE DENSITY CONSERVATION AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE;

EID: 73849110516     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000252838     Document Type: Article

References (17)

1. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR, for the Study of Osteoporotic Features Research Group: Older women with diabetes have an increased risk of fracture: A prospective study. J Clin Endocrinol Metab 2001; 86: 32-38.
2. Greving JP, Denig P, Ceeuw D, Bilo HJK, Haaijer-Ruskamp FM: Trends in hyperlipidemia and hypertension management in type diabetes from 1998-2004: A longitudinal observational study. Cardiovasc Diabetol 2007; 6: 25.
3. Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, Anderson PW: Post hoc analysis of data from the multiple outcomes of raloxifene evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25: 919-930.
4. Hadiadj S, Gourdy P, Zaoui P, Guerci B, Roudaut N, Gautier JF, Chabin M, Mauco G, Ragot S: Effect of raloxifene-a selective oestrogen receptor modulator-on kidney function in post-menopausal women with type 2 diabetes: Results from a randomized, placebo-controlled pilot trial. Diabet Med 2007; 24: 906-910.
5. Murase Y, Kobayashi J, Asano A, Yamaaki N, Yonezawa K, Muramoto H, Mabuchi H: Effects of raloxifene on adipocytokines in Japanese osteoporotic postmenopausal women with and without type 2 diabetes. Horm Metab Res 2006; 48: 130-133.
6. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C: A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835-842.
7. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-1451.
8. Friedewald WT, Levy RI, Fredrickson DS: Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
9. Nakamura Y, Saitoh S, Takagi S, Ohnishi H, Chiba Y, Kato N, Akasaka H, Miura T, Tsuchihashi K, Shimamoto K: Impact of abnormal glucose tolerance, hypertension and other risk factors on coronary artery disease. Circ J 2007; 71: 20-25.
10. Insull W Jr, Davidson MH, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA: Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 2005; 54: 939-946.
11. Piperi C, Kalofoutis C, Skenderi K, Economidou O, Kalofoutis A: Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. J Obstet Gynaecol 2004; 24: 414-419. (Pubitemid 38824095)
12. Barrett-Conner E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK, for the Raloxifene Use for the Heart (RUTH) Trial Investigators: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-137.
13. Francucci CM, Daniele P, Iori N, Camilletti A, Massi F, Boscaro M: Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. J Endocrinol Invest 2005; 28: 623-631.
14. Tsai KS, Yen ML, Pan HA, Wu MH, Cheng WC, Hsu SH, Yen BL, Huang KE: Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001; 12: 1020-1025.
15. Song EK, Yeom JH, Shin HT, Kim SH, Shin EG, Oh JM: Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy. J Clin Pharm Ther 2006; 31: 421-427.
16. Anderson B, Johannsson G, Holm G, Bengtsson BA, Sashegyi A, Pavo I, Mason T, Anderson PW: Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: A randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 122-128.
17. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen PS, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE: Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508.